Just 12 African countries have hit WHO’s 10% vaccination target as supply chain issues worsen.
Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.
Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.
In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.
South Korean officials have urged the US government to help Korean companies gain access to IP related to producing COVID-19 jabs.
Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyers Squibb owned Juno Therapeutics over a cancer treatment patent.
Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.